Randomized Phase II Trial of Prolonged Overnight Fasting and/or Exercise on Fatigue and Other Patient Reported Outcomes in Women with Hormone Receptor Positive Advanced Breast Cancer (FastER)
长期隔夜禁食和/或运动对激素受体阳性晚期乳腺癌女性患者疲劳和其他患者报告结果的随机 II 期试验 (FastER)
基本信息
- 批准号:10714371
- 负责人:
- 金额:$ 81.06万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-09-20 至 2028-08-31
- 项目状态:未结题
- 来源:
- 关键词:AddressAdvanced Malignant NeoplasmAdverse effectsAnxietyAromatase InhibitorsAttenuatedBiological MarkersBody CompositionC-reactive proteinCDK4 geneCarbohydratesChemotherapy and/or radiationCircadian RhythmsCyclin-Dependent Kinase InhibitorDataDevelopmentDietDietary InterventionDoseEatingEffectivenessEnrollmentEvaluationExerciseFastingFatigueFulvestrantGoalsHormone ReceptorHourIndividualInflammationInflammatoryInterleukin-6Intermittent fastingInterventionLifeMediatingMenopausal SymptomMental DepressionMetastatic breast cancerMinority GroupsMood DisordersNeutropeniaOutcomeOutcome StudyParticipantPatient Outcomes AssessmentsPatientsPharmaceutical PreparationsPhasePhysical FunctionPhysical activityPhysical assessmentPilot ProjectsPopulationQuality of lifeRandomizedRandomized, Controlled TrialsReportingResearchRiskSamplingSleepSleep disturbancesTNF geneTestingToxic effectTreatment Side EffectsTreatment-related toxicityUnderrepresented MinorityWell in selfWomanacceptability and feasibilityadvanced breast canceradvanced diseaseadverse outcomeattentional controlcancer initiationcancer therapychemotherapycircadiandiet and exerciseethnic diversityexercise intensityexercise interventionexercise trainingexperiencefeasibility testinggastrointestinalhormone receptor-positivehormone therapyimprovedimproved outcomeimprovement on sleepinflammatory markerinhibitorinhibitor therapyintervention effectlifestyle interventionmalignant breast neoplasmnovelpatient populationphase II trialpost interventionpreservationprimary outcomepsychologicsecondary outcomeside effecttargeted treatmenttumor
项目摘要
Abstract
More than 40,000 women die each year of metastatic breast cancer. The majority of these tumors are hormone
receptor positive (HR+) that are treated with a cyclin dependent kinase 4/6 (CDK4/6) inhibitor in combination
with an aromatase inhibitor or fulvestrant. With these treatments, women with advanced breast cancer are
living longer, but treatment related toxicities inevitably occur, and quality of life is limited by side effects of
cancer treatment which may result in dose reductions and delays. Fatigue is the most commonly cited adverse
side effect reported for women taking CDK4/6 inhibitors and mechanistically may be associated with
inflammation. When unmanaged, fatigue is debilitating directly impacting both psychological and physical
quality of life and a key driver in discontinuation of therapy. Lifestyle interventions targeting diet and exercise
have evidence for improving fatigue in early stage breast cancer, however whether these strategies are
efficacious for improving outcomes in women with advanced breast cancer remains unknown, with even less
information for women from underrepresented backgrounds, who suffer disproportionately from breast cancer
and its treatment. Research regarding the impact of these strategies on high grade fatigue induced by CDK4/6
inhibitors in advanced disease from a diverse patient population are needed.
The prolonged overnight Fasting and/or Exercise on fatigue and other patient reported
outcomes in women with hormone Receptor positive advanced breast cancer (FastER) study, will
evaluate a phase II, 2 x 2 randomized controlled trial testing the effects of a prolonged overnight fasting (POF)
intervention alone, moderate-intensity exercise alone, or in combination, on fatigue in 260 women with
advanced breast cancer initiating treatment with hormonal therapy in combination with a CDK4/6 inhibitor.
Participants would undergo assessment of fatigue and associated inflammatory biomarkers, as well as
assessment of physical activity, diet, physical function, body composition and patient reported outcomes at
baseline (prior to the initiation of CDK4/6 inhibitor) and 12 weeks (post-intervention), 6 and 12 months after
study enrollment. The primary outcome of the study is to evaluate the impact of the interventions (vs control)
on fatigue in women at 12 weeks. Secondary outcomes include inflammatory biomarkers, patient-reported
outcomes, physical function and body composition. The FastER study will also explore the impact of the
intervention on circadian rhythms, fatigue, sleep, depression, anxiety, quality of life, physical function and body
composition.
The overarching goal of the FastER study is to determine whether prolonged overnight fasting or moderate-
intensity exercise alone or in combination can mitigate the adverse consequences of treatment and improve
fatigue and other outcomes, in women with advanced breast cancer treated with CDK4/6 inhibitors to ultimately
improve both quantity and quality of life for this growing population of women.
抽象的
每年有超过 40,000 名女性死于转移性乳腺癌。这些肿瘤大多数是激素性的
联合使用细胞周期蛋白依赖性激酶 4/6 (CDK4/6) 抑制剂治疗的受体阳性 (HR+)
与芳香酶抑制剂或氟维司群一起使用。通过这些治疗,患有晚期乳腺癌的女性可以
寿命更长,但不可避免地会发生与治疗相关的毒性,并且生活质量受到副作用的限制
癌症治疗可能会导致剂量减少和延迟。疲劳是最常见的不良反应
据报道,服用 CDK4/6 抑制剂的女性会出现副作用,从机制上讲,可能与
炎。如果不加以管理,疲劳会直接影响心理和身体
生活质量和停止治疗的关键驱动因素。针对饮食和运动的生活方式干预
有证据表明可以改善早期乳腺癌的疲劳,但是这些策略是否有效
对于改善晚期乳腺癌女性的预后是否有效仍然未知,甚至更少
为来自代表性不足的背景且罹患乳腺癌的女性比例过高的女性提供的信息
及其治疗。关于这些策略对 CDK4/6 引起的高级疲劳影响的研究
需要来自不同患者群体的晚期疾病抑制剂。
长时间过夜禁食和/或运动导致疲劳和其他患者报告
激素受体阳性晚期乳腺癌 (FastER) 女性研究的结果
评估 II 期 2 x 2 随机对照试验,测试长时间禁食 (POF) 的影响
对 260 名患有疲劳症的女性进行单独干预、单独中等强度运动或联合使用,以缓解疲劳
晚期乳腺癌开始采用激素疗法联合 CDK4/6 抑制剂进行治疗。
参与者将接受疲劳和相关炎症生物标志物的评估,以及
评估身体活动、饮食、身体机能、身体成分和患者报告的结果
基线(开始使用 CDK4/6 抑制剂之前)和 12 周(干预后)、干预后 6 个月和 12 个月
学习招生。该研究的主要结果是评估干预措施的影响(与对照相比)
12 周时女性的疲劳。次要结果包括炎症生物标志物、患者报告的
结果、身体机能和身体成分。 FastER 研究还将探讨
对昼夜节律、疲劳、睡眠、抑郁、焦虑、生活质量、身体机能和身体的干预
作品。
FastER 研究的总体目标是确定是长时间禁食还是适度禁食?
单独或组合进行强度运动可以减轻治疗的不良后果并改善
在接受 CDK4/6 抑制剂治疗的晚期乳腺癌女性中,疲劳和其他结果最终
提高不断增长的女性人口的生活数量和质量。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Tracy E Crane其他文献
Baseline characteristics and recruitment for SWOG S1820: altering intake, managing bowel symptoms in survivors of rectal cancer (AIMS-RC)
SWOG S1820 的基线特征和招募:改变摄入量,管理直肠癌幸存者的肠道症状 (AIMS-RC)
- DOI:
- 发表时间:
2024 - 期刊:
- 影响因子:3.1
- 作者:
Virginia Sun;Cynthia A. Thomson;Tracy E Crane;Kathryn B. Arnold;Katherine A. Guthrie;Sarah G. Freylersythe;C. Braun;Lee Jones;Joseph C Carmichael;Craig A Messick;Devin Flaherty;Samir Ambrale;Stacey A. Cohen;R. Krouse - 通讯作者:
R. Krouse
Tracy E Crane的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Tracy E Crane', 18)}}的其他基金
Trial of Exercise and Lifestyle (TEAL) in Women with Ovarian Cancer
卵巢癌女性运动和生活方式试验 (TEAL)
- 批准号:
10450928 - 财政年份:2022
- 资助金额:
$ 81.06万 - 项目类别:
Trial of Exercise and Lifestyle (TEAL) in Women with Ovarian Cancer
卵巢癌女性运动和生活方式试验 (TEAL)
- 批准号:
10626041 - 财政年份:2022
- 资助金额:
$ 81.06万 - 项目类别:
相似海外基金
Evaluating the relationship between immune checkpoint inhibitors and osteoarthritis
评估免疫检查点抑制剂与骨关节炎之间的关系
- 批准号:
10577306 - 财政年份:2023
- 资助金额:
$ 81.06万 - 项目类别:
Evaluation of Subtractive Immunopheresis for Treatment of Hormone-Refractive Advanced Breast Cancer
减法免疫去除术治疗激素折射晚期乳腺癌的评价
- 批准号:
10483880 - 财政年份:2022
- 资助金额:
$ 81.06万 - 项目类别:
Psilocybin Therapy for Advanced Cancer-related Psychiatric Distress
裸盖菇素治疗晚期癌症相关精神困扰
- 批准号:
10659059 - 财政年份:2022
- 资助金额:
$ 81.06万 - 项目类别:
Psilocybin Therapy for Advanced Cancer-related Psychiatric Distress
裸盖菇素治疗晚期癌症相关精神困扰
- 批准号:
10534022 - 财政年份:2022
- 资助金额:
$ 81.06万 - 项目类别:
Optimizing Pain Management in End-Stage Renal Disease Among Veterans (OPERA-Vets):Balancing Benefits and Harms of Opioids
优化退伍军人终末期肾病的疼痛管理 (OPERA-Vets):平衡阿片类药物的利弊
- 批准号:
10185425 - 财政年份:2021
- 资助金额:
$ 81.06万 - 项目类别: